^
Association details:
| Biomarker: | KRAS G13A |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3461 - Preclinical and clinical evaluation of the RAF/MEK clamp avutometinib (VS-6766) in combination with the mTOR inhibitor everolimus for the treatment of KRAS mutated non-small cell lung cancer
Published date:
03/15/2023
Excerpt:
The current objective response rate (ORR) among the 14 patients who have at least one post assessment scan is 3/14 (21%; 1 G12V, 1 G12A, 1 G13A) with 11/14 showing a reduction in tumor size as best response....We have shown that avutometinib and everolimus induce synergistic anti-tumor effects preclinically, and preliminary data suggest clinically meaningful ORR and PFS in patients with KRAS mt NSCLC including non-G12C variants.
Secondary therapy:
everolimus
